LifeStance Health Group (NASDAQ:LFST) Insider Sells $345,000.00 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the transaction, the insider directly owned 315,610 shares in the company, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

LifeStance Health Group Stock Performance

LifeStance Health Group stock opened at $7.05 on Monday. The firm has a fifty day simple moving average of $5.99 and a two-hundred day simple moving average of $5.37. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a market capitalization of $2.74 billion, a PE ratio of -235.00 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The firm had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. During the same quarter in the previous year, the business earned ($0.02) earnings per share. The company’s quarterly revenue was up 16.3% on a year-over-year basis. Research analysts expect that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LFST. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 15th. UBS Group increased their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Barclays started coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target on the stock. Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, BMO Capital Markets initiated coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently modified their holdings of LFST. AustralianSuper Pty Ltd bought a new stake in LifeStance Health Group during the 3rd quarter valued at approximately $17,056,000. Vanguard Group Inc. lifted its stake in shares of LifeStance Health Group by 19.5% in the 3rd quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after purchasing an additional 2,383,728 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new position in LifeStance Health Group in the third quarter worth $8,250,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.